Heranba Industries Ltd
Incorporated in 1994, Heranba Industries Ltd is engaged in the manufacturing of a diverse range of agrochemicals such as insecticides, herbicides, fungicides and public health products for pest control. [1]
- Market Cap ₹ 1,197 Cr.
- Current Price ₹ 299
- High / Low ₹ 678 / 294
- Stock P/E 8.65
- Book Value ₹ 197
- Dividend Yield 0.67 %
- ROCE 38.5 %
- ROE 30.4 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 56.2% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 33.4%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Agro Chemicals Industry: Pesticides / Agrochemicals - Indian
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | TTM | |
---|---|---|---|---|---|---|---|---|
514 | 582 | 741 | 1,004 | 951 | 1,219 | 1,450 | 1,416 | |
470 | 534 | 653 | 873 | 822 | 997 | 1,190 | 1,215 | |
Operating Profit | 44 | 48 | 88 | 131 | 129 | 221 | 260 | 201 |
OPM % | 9% | 8% | 12% | 13% | 14% | 18% | 18% | 14% |
1 | 2 | 5 | 7 | 17 | 7 | 19 | 14 | |
Interest | 13 | 12 | 12 | 11 | 9 | 5 | 4 | 6 |
Depreciation | 4 | 4 | 5 | 6 | 8 | 15 | 20 | 25 |
Profit before tax | 28 | 35 | 76 | 122 | 129 | 208 | 255 | 184 |
Tax % | 39% | 41% | 39% | 38% | 24% | 26% | 26% | |
Net Profit | 17 | 20 | 47 | 75 | 98 | 154 | 189 | 138 |
EPS in Rs | 21.61 | 26.01 | 60.02 | 19.31 | 25.00 | 38.54 | 47.25 | 34.58 |
Dividend Payout % | 13% | 10% | 9% | 5% | 6% | 4% | 4% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 20% |
3 Years: | 13% |
TTM: | 3% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 56% |
3 Years: | 36% |
TTM: | -27% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | -54% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 34% |
3 Years: | 33% |
Last Year: | 30% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Sep 2022 | |
---|---|---|---|---|---|---|---|---|
8 | 8 | 8 | 39 | 39 | 40 | 40 | 40 | |
Reserves | 91 | 108 | 150 | 189 | 282 | 488 | 674 | 748 |
96 | 84 | 76 | 50 | 43 | 52 | 54 | 97 | |
130 | 120 | 217 | 282 | 261 | 263 | 300 | 439 | |
Total Liabilities | 325 | 321 | 450 | 560 | 625 | 843 | 1,069 | 1,325 |
37 | 38 | 46 | 51 | 95 | 133 | 193 | 194 | |
CWIP | 0 | 0 | 1 | 16 | 38 | 10 | 14 | 35 |
Investments | 0 | 0 | 0 | 0 | 4 | 10 | 2 | 1 |
287 | 282 | 403 | 493 | 488 | 690 | 859 | 1,095 | |
Total Assets | 325 | 321 | 450 | 560 | 625 | 843 | 1,069 | 1,325 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|
52 | 54 | 60 | 98 | ||||
-25 | -52 | -41 | -82 | ||||
-26 | -20 | 62 | -6 | ||||
Net Cash Flow | 1 | -18 | 82 | 10 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|
Debtor Days | 102 | 78 | 100 | 92 | 99 | 102 | 103 |
Inventory Days | 76 | 86 | 68 | 60 | 83 | 78 | 100 |
Days Payable | 96 | 84 | 129 | 123 | 122 | 92 | 95 |
Cash Conversion Cycle | 83 | 79 | 39 | 29 | 61 | 89 | 108 |
Working Capital Days | 98 | 89 | 76 | 58 | 83 | 96 | 109 |
ROCE % | 24% | 41% | 52% | 43% | 45% | 38% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
16 Mar - Interactions with investors / analysts are scheduled to take place, the details of which are given in the letter attached herewith.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
20 Feb - Interactions with investors / analysts are scheduled to take place, the details of which are given in the Letter attached.
-
Announcement under Regulation 30 (LODR)-Credit Rating
10 Feb - CRISIL Rating Limited (A Credit Rating Agency 'CRISIL') vide its Letter dated February 09, 2023 has submitted its report regarding the rating outstanding for the …
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
8 Feb - Interactions with investors / analysts are scheduled to take place, the details of which are given in the Letter attached.
-
Announcement under Regulation 30 (LODR)-Acquisition
4 Feb - It has acquired 6,000 Equity Shares of Heranba Industries Limited from Open Market (NSE ) from February 01, 2023 to February 03, 2023 .Enclosing herewith …
Concalls
-
Feb 2023TranscriptPPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Jan 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021TranscriptNotesPPT
Product Portfolio
The Co.’s portfolio comprises intermediates, technicals and formulations.
Intermediates: Intermediates manufactured are for Co.’s own captive consumption for manufacturing various Technicals and Formulations. [1] These include CMAC, Bromobenzenes, Metaphenoxy, etc.
Technicals: These include Cypermethrin, Deltamethrin, Alpha Cypermethrin, Acephate, Lambda Cyhalothrin, etc.
Formulations: Formulations and branding of formulations are a forward integration to Heranba’s technical business. These include Emulsifiable Concentrate (EC), Water Dispersible Granule (WDG), Suspension concentrate, Capsule Suspension (CS), etc.
It has 400 product registrations in 49 countries,210 registrations in pipeline in 49 countries. 24 Technicals,193 formulations are registered for manufacture & sale in India.68 technicals & 65 formulations are registered for manufacture and sale in export markets
{#https://www.bseindia.com/bseplus/AnnualReport/543266/73414543266_05_07_22.pdf#page=4 #}